Daniel J. Hicklin

机构：C4 Therapeutics (United States), Werewolf Therapeutics (United States) · ORCID：0009-0005-3474-9348

发表论文 348 篇 · 总被引 53460 次 · h-index 103

代表论文

• Abstract 4074: Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models (2024 · Cancer Research · 被引 2)
• 964 Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity (2025 · Regular and Young Investigator Award Abstracts · 被引 1)
• Abstract 4078: WTX-712, a conditionally active IL-21 INDUKINETM molecule, induces a strong anti-tumor phenotype through a differentiated mechanism (2024 · Cancer Research · 被引 1)
• Supplemental Figure 3 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins (2026)
• Supplemental Figure 1 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins (2026)
• Supplemental Figure 5 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins (2026)